Hem › Diffust storcelligt B-cellslymfom › Texas › Houston
Kliniska studier för Diffust storcelligt B-cellslymfom i Houston, TX
17 studier för Diffust storcelligt B-cellslymfom söker deltagare vid platser i och runt Houston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekryterarFas 2
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekryterarObservationsstudie
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekryterarFas 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RekryterarFas 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekryterarFas 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekryterarFas 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekryterarFas 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekryterarFas 1
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekryterarFas 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekryterarFas 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekryterarFas 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RekryterarFas 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekryterarFas 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekryterarFas 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekryterarFas 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RekryterarFas 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
RekryterarFas 1
- MD Anderson Cancer Center, Houston
Diffust storcelligt B-cellslymfom-studier i andra städer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Los Angeles, CA17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Nashville, TN15 studier
- Portland, OR15 studier
- Philadelphia, PA15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andra studier i Houston
- Icke-småcellig lungcancer145 studier
- Bröstcancer126 studier
- Cancer (alla typer)121 studier
- Metastaserande cancer104 studier
- Kolorektal cancer102 studier
- Äggstockscancer89 studier
- Akut myeloid leukemi85 studier
- Lungcancer78 studier
- Prostatacancer76 studier
- Endometriecancer68 studier
- Bukspottkörtelcancer61 studier
- Melanom59 studier
Från ClinicalTrials.gov, data hämtad 4 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.